Skip to main content

Table 1 The detailed demographic and clinical characteristics of every ET-PD patient

From: Ultrasonographic (TCS) and clinical findings in overlapping phenotype of essential tremor and Parkinson’s disease (ET-PD)

No. Symp. durat. FH Topography Later. Extr. tone SN+ Pharmacotherapy
1. 43 Yes H + A D Yes Yes DA, amantadine 200 mg, propranolol 80 mg
2. 6 Yes H + A D No No DA, clorazepate 10 mg
3. 21 No A + L B No Yes Propranolol 120 mg, clonazepam 2 mg
4. 3.5 Yes H + A S No Yes L-Dopa, pregabaline 75 mg
5. 10 No H + A D No Yes DA, bromazepam 1.5 mg, vit. E
6. 30 Yes H + A D No No L-Dopa
7. 6 No H + V + A D Yes Yes L-Dopa, DA, propranolol 80 mg, citalopram,
clonazepam 0.25 mg
8. 10 Yes A + L B Yes No L-Dopa, propranolol 80 mg
9. 11 No H + A + L B Yes Yes L-Dopa, DA, rasagiline 1 mg
10. 15 No A D No No Sertraline, zolpidem
11. 3 No A S No Yes Propranolol 40 mg
12. 45 Yes A S No Yes L-Dopa, DA
13. 3 Yes H + V + A D No Yes Clonazepam 2 mg, tiapride 150 mg
14. 1.5 Yes H + A S No Yes Paroxetine, clonazepam 0.25 mg, vit. E, coenzyme Q10
15. 10 No A B No No Gabapentine 100 mg, vinpocetine 20 mg, piracetam 400 mg, vit. E